

# Irina Velikyan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150888/publications.pdf>

Version: 2024-02-01

65  
papers

2,213  
citations

279798

23  
h-index

233421

45  
g-index

68  
all docs

68  
docs citations

68  
times ranked

2377  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. <i>Cell Metabolism</i> , 2022, 34, 59-74.e10.  | 16.2 | 92        |
| 2  | Abstract P3-02-06: A phase II study of <sup>68</sup> Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer. <i>Cancer Research</i> , 2022, 82, P3-02-06-P3-02-06.  | 0.9  | 1         |
| 3  | Comparison of <sup>68</sup> Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer. <i>European Journal of Hybrid Imaging</i> , 2022, 6, 5.  | 1.5  | 5         |
| 4  | PET-CT imaging of pulmonary inflammation using [ <sup>68</sup> Ga]Ga-DOTA-TATE. <i>EJNMMI Research</i> , 2022, 12, 19.  | 2.5  | 6         |
| 5  | Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type I. <i>Nuclear Medicine and Biology</i> , 2021, 93, 54-62.  | 0.6  | 10        |
| 6  | Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 833-838.  | 5.0  | 9         |
| 7  | Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography. <i>Diabetes</i> , 2021, 70, 842-853.  | 0.6  | 10        |
| 8  | Prospective data-driven respiratory gating of [ <sup>68</sup> Ga]Ga-DOTATOC PET/CT. <i>EJNMMI Research</i> , 2021, 11, 33.  | 2.5  | 9         |
| 9  | Theranostic Approach in Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, e410-e420.  | 1.3  | 31        |
| 10 | Exploring the GLP-1â€“GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002083.   | 2.8  | 2         |
| 11 | <sup>68</sup> Gaâ€“DOTATOCâ€“PET/MRI and <sup>11</sup> Câ€“5â€“HTPâ€“PET/MRI are superior to <sup>68</sup> Gaâ€“DOTATOCâ€“PET/CT for neuroendocrine tumour imaging. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12981.                      | 2.6  | 12        |
| 12 | Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262506.   | 5.0  | 2         |
| 13 | Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. <i>Scientific Reports</i> , 2021, 11, 19151.   | 3.3  | 8         |
| 14 | Improved Radiolytic Stability of a <sup>68</sup> Ga-labelled Collagelin Analogue for the Imaging of Fibrosis. <i>Pharmaceuticals</i> , 2021, 14, 990.   | 3.8  | 3         |
| 15 | Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by <sup>68</sup> Ga-DOTATOC PET/CT. <i>EJNMMI Research</i> , 2021, 11, 118. | 2.5  | 8         |
| 16 | Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using <sup>68</sup> Ga-DOTATOC and <sup>68</sup> Ga-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2020, 61, 217-221.                               | 5.0  | 20        |
| 17 | Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. <i>Theranostics</i> , 2020, 10, 437-461.   | 10.0 | 29        |
| 18 | Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes. <i>Scientific Reports</i> , 2020, 10, 16758.  | 3.3  | 28        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | GMP production of [ <sup>68</sup> Ga]Ga-BOT5035 for imaging of liver fibrosis in microdosing phase 0 study. Nuclear Medicine and Biology, 2020, 88-89, 73-85.   | 0.6  | 4         |
| 20 | Automated GMP-Compliant Production of [ <sup>68</sup> Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans. Pharmaceuticals, 2020, 13, 176.   | 3.8  | 4         |
| 21 | (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals, 2020, 13, 39.   | 3.8  | 10        |
| 22 | Comparison of <sup>68</sup> Ga-PSMA-11 PET/CT with <sup>11</sup> C-acetate PET/CT in re-staging of prostate cancer relapse. Scientific Reports, 2020, 10, 4993.   | 3.3  | 9         |
| 23 | Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [ <sup>11</sup> C]-Acetate PET/CT. International Journal of Medical Sciences, 2020, 17, 214-223.  | 2.5  | 5         |
| 24 | In Vivo Instability of <sup>177</sup> Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2020, 61, 1337-1340.   | 5.0  | 17        |
| 25 | Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Research, 2020, 10, 21.  | 2.5  | 11        |
| 26 | First-in-class positron emission tomography tracer for the glucagon receptor. EJNMMI Research, 2019, 9, 17.   | 2.5  | 21        |
| 27 | Regularized reconstruction of digital time-of-flight <sup>68</sup> Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients. Theranostics, 2019, 9, 3476-3484.  | 10.0 | 24        |
| 28 | Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. Scientific Reports, 2019, 9, 14960.  | 3.3  | 11        |
| 29 | Diagnostic HER2-binding radiopharmaceutical, [ <sup>68</sup> Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 12-23.                               | 1.0  | 15        |
| 30 | Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [ <sup>68</sup> Ga]Ga-DO3A-VS-Cys40-Exendin-4 /PET. Scientific Reports, 2018, 8, 748.  | 3.3  | 5         |
| 31 | Prospective of <sup>68</sup> Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation. Contrast Media and Molecular Imaging, 2018, 2018, 1-24.  | 0.8  | 33        |
| 32 | Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1337-1346. | 6.4  | 39        |
| 33 | Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4. Acta Diabetologica, 2017, 54, 1039-1045.   | 2.5  | 27        |
| 34 | Parametric Net Influx Rate Images of <sup>68</sup> Ga-DOTATOC and <sup>68</sup> Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. Journal of Nuclear Medicine, 2017, 58, 744-749.   | 5.0  | 23        |
| 35 | Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals, 2017, 10, 30.   | 3.8  | 44        |
| 36 | Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers. Oncotarget, 2017, 8, 65152-65170.  | 1.8  | 9         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [ <sup>68</sup> Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016, 6, 262-271.   | 10.0 | 204       |
| 38 | Feasibility of Multiple Examinations Using <sup>68</sup> Ga-Labelled Collagelin Analogues: Organ Distribution in Rat for Extrapolation to Human Organ and Whole-Body Radiation Dosimetry. <i>Pharmaceuticals</i> , 2016, 9, 31.                                      | 3.8  | 7         |
| 39 | Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule <sup>68</sup> Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.   | 5.0  | 88        |
| 40 | Quantification of Î²-Cell Mass in Intramuscular Islet Grafts Using Radiolabeled Exendin-4. <i>Transplantation Direct</i> , 2016, 2, e93.   | 1.6  | 12        |
| 41 | Feasibility of ( <sup>68</sup> Ga)-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a porcine model of acute respiratory distress syndrome. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 18-31. | 1.0  | 16        |
| 42 | Good manufacturing practice production of [( <sup>68</sup> Ga)Ga]-ABY-025 for HER2 specific breast cancer imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 135-53.  | 1.0  | 15        |
| 43 | <sup>68</sup> Ga-Based Radiopharmaceuticals: Production and Application Relationship. <i>Molecules</i> , 2015, 20, 12913-12943.  | 3.8  | 179       |
| 44 | The effect of macrocyclic chelators on the targeting properties of the <sup>68</sup> Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. <i>Nuclear Medicine and Biology</i> , 2015, 42, 446-454.  | 0.6  | 46        |
| 45 | Continued rapid growth in <sup>68</sup> Ga applications: update 2013 to June 2014. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 99-121.   | 1.0  | 57        |
| 46 | Non-invasive determination of HER2-expression in metastatic breast cancer by using <sup>68</sup> Ga-ABY025 PET/CT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11067-11067.   | 1.6  | 0         |
| 47 | Dosimetry of [( <sup>177</sup> Lu)-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 109-26.   | 1.0  | 16        |
| 48 | Dosimetry of [( <sup>68</sup> Ga)Ga]-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possible. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 259-69.                         | 1.0  | 25        |
| 49 | The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a <sup>68</sup> Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. <i>Molecules</i> , 2014, 19, 10455-10472.  | 3.8  | 55        |
| 50 | Radionuclides for Imaging and Therapy in Oncology. , 2014, , 285-325.  |      | 8         |
| 51 | Prospective of <sup>68</sup> Ga-Radiopharmaceutical Development. <i>Theranostics</i> , 2014, 4, 47-80.   | 10.0 | 265       |
| 52 | Pre-clinical evaluation of [ <sup>68</sup> Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma. <i>Nuclear Medicine and Biology</i> , 2014, 41, 471-476.   | 0.6  | 27        |
| 53 | Quantitative and Qualitative Inpatient Comparison of <sup>68</sup> Ga-DOTATOC and <sup>68</sup> Ga-DOTATATE: Net Uptake Rate for Accurate Quantification. <i>Journal of Nuclear Medicine</i> , 2014, 55, 204-210.  | 5.0  | 135       |
| 54 | Synthesis and preclinical evaluation of <sup>68</sup> Ga-labeled collagelin analogs for imaging and quantification of fibrosis. <i>Nuclear Medicine and Biology</i> , 2014, 41, 728-736.   | 0.6  | 24        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | The Diversity of <sup>68</sup> Ga-Based Imaging Agents. <i>Recent Results in Cancer Research</i> , 2013, 194, 101-131.   | 1.8  | 11        |
| 56 | Organ biodistribution of Germanium-68 in rat in the presence and absence of [( <sup>68</sup> Ga)Ga-DOTA-TOC for the extrapolation to the human organ and whole-body radiation dosimetry. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 154-65.                        | 1.0  | 8         |
| 57 | Preclinical evaluation of a <sup>68</sup> Ga-labeled biotin analogue for applications in islet transplantation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 415-421.   | 0.6  | 12        |
| 58 | Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. <i>Nuclear Medicine and Biology</i> , 2012, 39, 628-639.   | 0.6  | 21        |
| 59 | Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management. <i>Theranostics</i> , 2012, 2, 424-426.  | 10.0 | 64        |
| 60 | In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and ( <sup>67</sup> / <sup>68</sup> Ga)-labeled haptens by pretargeting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 141-50. | 1.0  | 13        |
| 61 | Synthesis and characterization of scVEGF-PEG-[ <sup>68</sup> Ga]NOTA and scVEGF-PEG-[ <sup>68</sup> Ga]DOTA PET tracers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 685-692.  | 1.0  | 12        |
| 62 | Positron Emitting [ <sup>68</sup> Ga]Ga-Based Imaging Agents: Chemistry and Diversity. <i>Medicinal Chemistry</i> , 2011, 7, 345-379.  | 1.5  | 53        |
| 63 | In vivo binding of [ <sup>68</sup> Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours – impact of peptide mass. <i>Nuclear Medicine and Biology</i> , 2010, 37, 265-275.  | 0.6  | 122       |
| 64 | <sup>68</sup> Ga-Labeling of Biotin Analogues and their Characterization. <i>Bioconjugate Chemistry</i> , 2009, 20, 1146-1151.   | 3.6  | 28        |
| 65 | Preparation and evaluation of ( <sup>68</sup> Ga)-DOTA-hEGF for visualization of EGFR expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1881-8.   | 5.0  | 90        |